The effectiveness of vitrectomy co-adjuvant intravitreal dexamethasone implant on visual outcome in patients with proliferative diabetic retinopathy: study protocol for a prospective randomized controlled trail

The effectiveness of vitrectomy co-adjuvant intravitreal dexamethasone implant on visual outcome in patients with proliferative diabetic retinopathy: study protocol for a prospective randomized controlled trail | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article The effectiveness of vitrectomy co-adjuvant intravitreal dexamethasone implant on visual outcome in patients with proliferative diabetic retinopathy: study protocol for a prospective randomized controlled trail 萌 赵, Aman Chandra, Jun Xu, Lin Liu, Jipeng Li This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3622174/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 12 Feb, 2025 Read the published version in Trials → Version 1 posted 4 You are reading this latest preprint version Abstract Background : Proliferative diabetic retinopathy (PDR) often leads to tractional retinal detachment and vitreous hemorrhage, requiring vitrectomy. Poor visual outcomes are commonly caused by macular edema and proliferative vitreous retinopathy after vitrectomy. Intravitreal dexamethasone implant has shown promise in improving visual function after vitrectomy for diabetic macular edema, but its role in vitrectomy in PDR treatment remains unexplored. This study aims to assess the effectiveness of vitrectomy combined with intravitreal dexamethasone implant for PDR patients. Methods : We designed a single-blind, randomized controlled trial with 100 participants diagnosed with PDR requiring vitrectomy. Participants were randomly assigned to either the dexamethasone implant group or the control group. The dexamethasone implant group underwent vitrectomy combined with intravitreal dexamethasone implant, while the control group underwent vitrectomy alone. The single surgeon performed all the vitrectomy surgeries, the choice of intravitreal dexamethasone implant treatment was disclosed before the closure of scleral wounds. Primary and secondary outcomes were assessed at baseline, 4 weeks, and 8 weeks post-vitrectomy. Primary outcome measures included corrected visual acuity (Snellen visual chart) and central retinal thickness (optical coherence tomography OCT). Secondary outcomes included elevated intraocular pressure, post-vitrectomy hemorrhage, retinal detachment, and systemic complications requiring hospitalization. Discussion : This protocol seeks to enhance our understanding of the effects of combined intravitreal dexamethasone implant with vitrectomy on visual outcomes and macular morphology changes in treating late complications of PDR. The trail was registered at Chinese Clinical Trial Registry at May 11 th 2022 with registration number ChiCTR2200059760. intravitreal dexamethasone implant vitrectomy proliferative diabetic retinopathy Figures Figure 1 Administrative Information Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/). Title {1} The effectiveness of vitrectomy co-adjuvant intravitreal dexamethasone implant on visual outcome in patients with proliferative diabetic retinopathy: study protocol for a prospective randomized controlled trail. Trial registration {2a and 2b}. ChiCTR2200059760, Chinese Clinical Trial Registry Protocol version {3} 2022-9-9, Version 20220909 Funding {4} This study was not supported by any funding. Author details {5a} Jipeng Li1, Aman Chandra2, Jun Xu1, Lin Liu 1, Meng Zhao1 1 Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University. No1. Dongjiaominxiang street, Dongcheng District, Beijing,100730, China. 2 Mid & South Essex NHS Foundation Trust (Southend University Hospital) Prittlewell Chase Essex SS00RY, UK; Anglia Ruskin University, Cambridge, UK. Name and contact information for the trial sponsor {5b} Primary investigator who initiate the research: Jipeng Li, [email protected] Role of sponsor {5c} The sponsor play a role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. Introduction Background and rationale {6a} SPIRIT guidance: Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention. Proliferative diabetic retinopathy (PDR) is one of the major diseases threatening the vision of the working population[1] . China has a high prevalence of diabetes, and the incidence of diabetes is rapidly increasing[2]. When PDR progresses to the stage of tractional retinal detachment or recurrent vitreous hemorrhage (VH), vitrectomy is required to salvage the remaining vision[3] . However, a long-term follow-up study involving 217 PDR patients who underwent vitrectomy showed that the rates of low vision at 1 year, 5 years, and 10 years after surgery were 24%, 31%, and 39%, respectively. Most complications occurred within the first year after surgery, with the top three being elevated intraocular pressure (37%), macular edema (29%), and retinal detachment (12%)[4] . Moreover, there is often a certain degree of intraocular inflammatory response after vitrectomy surgery[5], which can lead to macular edema, vitreous cavity proliferative changes, affecting postoperative visual recovery, and possibly necessitating further surgery. Diabetic patients often have complex systemic abnormalities，which limits systemic steroid as a routine postoperative anti-inflammatory treatment. Intraocular dexamethasone sustained-release system, administered via a minimally invasive injection, has emerged as a delivery route for ocular therapeutics and has found widespread application in diabetic macular edema (DME) [6] . It has been considered both effective and safe [7,8]. A prospective study involving patients with refractory DME following vitrectomy (55 patients over 26 weeks) demonstrated that intravitreal injection of dexamethasone sustained-release system after vitrectomy is a safe and effective treatment modality [9]. Earlier small-scale clinical trials (23 patients followed for 6 months) have shown that combining vitrectomy in diabetic patients with intravitreal dexamethasone sustained-release system injection and silicone oil tamponade helps alleviate tractional macular edema and reduces the need for postoperative intravitreal injections of other anti-inflammatory agents (such as anti-vascular endothelial growth factor agents), and this combined treatment approach has been proven to be safe during follow-up [10]. However, the severity of PDR was not addressed in these aforementioned studies, and there is a scarcity of case reports on PDR cases involving tractional retinal detachment in the macular area. Limited reports are available for severe PDR cases that did not undergo preoperative retinal laser therapy. Therefore, there exists a research gap in the observation of patients with severe, untreated PDR. These patients often require complex surgical interventions due to extensive peripheral retinal detachments, which include combined cataract surgery, intraoperative pan-retinal photocoagulation, and postoperative gas tamponade, thereby increasing the likelihood of postoperative inflammatory reactions. Objectives {7} SPIRIT guidance: Specific objectives or hypotheses. In China, many diabetic patients experience untreated progressive PDR lesions. These patients present with recurrent vitreous hemorrhage and tractional retinal detachment involving the macula at the initial consultation, with a lack of adequate previous photocoagulation or intravitreal anti-VEGF treatments. Such patients often require extensive intraoperative laser therapy and intraocular tamponade, leading to potentially heightened postoperative inflammatory responses. Our study aims to address the limitations of previous research by collecting a more diverse group of complex PDR patients. This will allow for a more comprehensive evaluation of the effectiveness and safety of this medication in the context of vitrectomy for progressive DR. Therefore, this study aims to conduct a prospective randomized controlled trial on patients with untreated PDR requiring vitrectomy. The study aims to observe the differences between vitrectomy combined with intravitreal dexamethasone sustained-release implant system injection and simple vitrectomy in terms of postoperative inflammatory reactions, postoperative visual improvement, resolution of DME, as well as common postoperative complications like postoperative VH and intraocular pressure fluctuations. The goal is to understand the efficacy and safety of vitrectomy combined with intravitreal dexamethasone sustained-release implant system in patients with PDR. Based on previous research findings, the incidence of postoperative macular edema in PDR is 29%, with 18% occurring within one year post-surgery [4]. In PDR patients who had pre-existing macular edema before surgery, the rate of resolution of macular edema after vitrectomy is only 22.9-29% [11]. We hypothesize that by combining intravitreal injection of dexamethasone sustained-release system with vitrectomy, we can reduce the incidence of postoperative macular edema and improve the resolution of pre-existing macular edema, thereby enhancing visual function. Trial design {8} SPIRIT guidance: Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory). A single-blind randomized control trial will be conducted to compare the effects of vitrectomy combined with intravitreal dexamethasone implant with vitrectomy (Fig. 1). The study will be conducted for 24 weeks (6 months), and this period will include a 24-week follow-up period with primary outcomes measured at baseline, 4, 8, 12 weeks and secondary outcomes measured at baseline, 4, 8,12,24 weeks. The allocation ratio is set at 1. The framework is exploratory. Methods: Participants, interventions and outcomes Study setting {9} Beijing Tongren eye center, an tertiary academic hospital, will serve as the primary site for the study. The data will be collected at the same center. Eligibility criteria {10} SPIRIT guidance: Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists). Inclusion Criteria: Patients with PDR will be included in the study if they meet one of the following three criteria: 1) presence of tractional retinal detachment involving the macula or an area adjacent to the macula, as confirmed by clinical examination; 2) presence of recurrent or non-absorbing vitreous haemorrhages; 3) simultaneous presence of vitreous haemorrhage and tractional retinal detachment confirmed by B-scan ultrasound examination when the fundus was obscured by vitreous haemorrhage. Additional inclusion criteria are as follows: Age between 18 and 70 years. Willingness to participate in the study and comply with scheduled follow-up visits. Exclusion criteria: Participants will be excluded from the study if any of the following conditions are reported: Presence of severe uncontrolled systemic abnormalities that contraindicated to vitrectomy surgery; Recent (<3month) administration of other intravitreal dexamethasone implant; History of glaucoma; History of conditions that may cause macular edema, such as uveitis or retinal vein occlusion; History of previous vitrectomy; Intraoperative identification of vitreous hemorrhage not caused by PDR; Inability of the patient to complete the scheduled follow-up visits Who will take informed consent? {26a} SPIRIT guidance: Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32). The primary investigator will obtain informed consent from the potential trial participants. Additional consent provisions for collection and use of participant data and biological specimens {26b} SPIRIT guidance: Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable. No secondary participant information or data will be collected, nor any biological specimens will be collected . Interventions Explanation for the choice of comparators {6b} SPIRIT guidance: Explanation for choice of comparators. The two comparators in this study are the vitrectomy combined with intravitreal dexamethasone implant group and the vitrectomy group (control group). These comparators were selected to evaluate the impact of vitrectomy combined with intravitreal dexamethasone implant on the visual outcomes and macular morphology of individuals with PDR during the 24-week post-vitrectomy period. By comparing these outcomes with those of individuals who underwent vitrectomy alone, the study aims to assess the effectiveness and safety of the intervention. The inclusion of a control group receiving vitrectomy alone allows for a comprehensive and clinically relevant evaluation of the intervention's effects in comparison to established treatment options. This approach ensures that the study findings can be extrapolated to real-world clinical practice, facilitating evidence-based decision-making in the management of PDR. Intervention description {11a} SPIRIT guidance: Interventions for each group with sufficient detail to allow replication, including how and when they will be administered. Vitrectomy: The patients underwent retrobulbar or general anesthesia. All patients underwent 23/25 gauge 3-port pars plana vitrectomy (PPV) using the Constellation Vision System (Alcon, Fort Worth, Texas, USA). Patients with active fibrovascular epiretinal proliferative membranes (FVMs) or severe vitreous hemorrhage (VH) obscuring the fundus received intravitreal ranibizumab (IVR) within seven days prior to vitrectomy, and the pre-vitrectomy IVR administration was documented. Following core vitrectomy, the presence of FVM, macular-involving tractional retinal detachment (TRD), and photocoagulation scars were documented. Triamcinolone acetonide-assisted vitrectomy was performed, releasing anterior-posterior vitreoretinal traction and inducing posterior vitreous detachment. Dissection, segmentation, delamination of FVM, endodiathermy, drainage of subretinal fluid, retinectomy, and intraocular tamponade were performed as needed for each patient. Peripheral vitrectomy with scleral indentation and endolaser photocoagulation were performed for all patients. Intraoperative bleeding was managed using techniques such as intraocular pressure elevation, perfluorocarbon liquids, and endodiathermy. Intravitreal dexamethasone implant: At the end of vitrectomy and before the closure of sclera incision, the dexamethasone implant was injected into the vitreous from the incision. Vitrectomy combined with intravitreal dexamethasone implant group: Patients in this group will receive vitrectomy and an intravitreal dexamethasone implant at the end of vitrectomy. Vitrectomy group: Patients in this group will receive vitrectomy only. Criteria for discontinuing or modifying allocated interventions {11b} SPIRIT guidance: Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease). Discontinuation Criteria: Observation endpoints for study discontinuation were defined as follows: 1) Patient completion of the 6-month follow-up period; 2) Patient requiring a second surgery for non-attached retina or non-absorption of vitreous hemorrhage; 3) Patient undergoing glaucoma surgery due to poor control of intraocular pressure with medication (including secondary to intraocular tamponade, uncontrolled neovascular glaucoma, or medication-induced); 4) Occurrence of uncontrolled intraocular inflammation; 5) Surgical removal of dislodged implant from the anterior chamber; 6) Deterioration of the patient's overall systemic condition preventing further follow-up; 7) Loss of visual acuity during the follow-up period or patient withdrawal from the treatment. Strategies to improve adherence to interventions {11c} SPIRIT guidance: Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests). All participants will receive preoperative education on PDR from the surgeon, emphasizing the significance of regular follow-up visits. During each follow-up appointment, scheduled plans for the next six months will be discussed individually with the participants, taking into consideration their availability and schedules. In the event that participants fail to adhere to the monthly follow-up schedule, the Principal Investigator (PI) will proactively contact the participant to ascertain the reasons for delayed presentation and investigate any underlying factors and rearrange the new schedule for follow-up if the participant could continue the previous follow-up plan. Relevant concomitant care permitted or prohibited during the trial {11d} SPIRIT guidance: Relevant concomitant care and interventions that are permitted or prohibited during the trial. No concomitant care and intervention requirements are either permitted or prohibited during the trial. The participants will be asked to maintain their medication dosage and any mandatory medical care or aid that they are receiving during the intervention period. Provisions for post-trial care {30} SPIRIT guidance: Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation. N/a. Outcomes {12} SPIRIT guidance: Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended. All outcome measures will be conducted by the researchers, binding to group allocation, at baseline, at 4,8,12,24- week follow-up after vitrectomy. Demographics, including age; gender; preoperative characteristics, including DM duration and DM medication, and the history of diabetes-related complications, including stroke, coronary artery disease (CAD), congenital heart failure, diabetic foot and chronic kidney disease, and hypertension; anticoagulation or antiplatelet medications; and ocular characteristics, including the history of previous photocoagulation, cataract phacoemulsification extraction, IV anti-VEGF agents, visual symptom duration will be collected. All the patients will go through a comprehensive ocular examination after enrollment, including corrected visual acuity (VA) tested by a Snellen decimal VA chart, intraocular pressure test by non-contact tonometer, silt lamp examination to evaluate lens status and the presence of iris neovascularization and neovascular glaucoma, binocular indirect ophthalmoscopy examination to evaluate severity of VH and FVP, B-scan ultrasound examination to identify retinal detachment and OCT scan to evaluate macular morphology if possible. Primary outcome measures: The primary outcome measures in this research protocol include corrected visual acuity at 12 weeks post-treatment. Baseline visual acuity and corrected visual acuity at 4, 8, and 12 weeks post-treatment will be measured using the LogMAR visual acuity chart. The assessment of corrected visual acuity will not involve the collection of biological samples. Corrected visual acuity serves as a universally recognized efficacy indicator for surgical treatment of PDR eyes. Secondary outcome measures: The secondary outcome measures in this research protocol encompass the following parameters: Retinal reattachment rate at 24 weeks post-vitrectomy evaluated by fundus examination using indirect binocular ophthalmoscopy. Central macular thickness on OCT at 12- and 24-weeks post-vitrectomy. Incidence of intraocular pressure elevation recorded at 12- and 24-weeks post-vitrectomy. Incidence of occurrence of postoperative vitreous hemorrhage during the 24-week followup after vitrectomy evaluated by fundus examination using indirect binocular ophthalmoscopy. Occurrence of subsequent cataract surgery in the following 24 weeks after vitrectomy. Incidence of choroidal detachment within 4 weeks post-vitrectomy. Among these measures, the retinal reattachment rate, incidence of postoperative vitreous hemorrhage, and occurrence of choroidal detachment are recognized efficacy indicators for surgical treatment. The rates of intraocular pressure elevation and subsequent cataract surgery serve as safety indicators for intraocular implantation. Central macular thickness on OCT is a widely accepted metric for evaluating macular morphology. The inclusion of these secondary outcome measures allows for a comprehensive evaluation of treatment efficacy, safety, and specific macular morphology changes associated with the intervention. Participant timeline {13} SPIRIT guidance: Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see figure at http://www.spirit-statement.org/publications-downloads/). Sample size {14} SPIRIT guidance: Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations. The estimated number of participants to achieve the study’s objectives is 39 per group, calculated to attain a 93% statistical power in the difference between two means of the independent variables for testing hypotheses with an alpha level of 5% and a minimal clinical important difference (MCID) of 1.13. This estimation is based on the calculation of the minimal clinical important difference that was determined based on the values obtained in past published studies[4] [9] [10]. Considering a 10-15% of dropout rate of the participants during the 24-week follow-up, the estimated number f participants is 50 per group. Recruitment {15} SPIRIT guidance: Strategies for achieving adequate participant enrolment to reach target sample size. Participants with PDR requiring vitrectomy will be recruited from the outpatients' clinics at Tongren Eye Center between October 2022 and October 2024 (The duration of patient recruitment is two years from the date of approval). The recruitment process will involve two sources, as outlined below: 1. Three retinal specialists, who collectively encounter over 60 PDR patients on a weekly basis, will oversee the recruitment of participants. These specialists will identify and approach eligible individuals for potential inclusion in the study. 2. Diabetic patients present at physicians at Tongren Hospital will be referred to the participated ophthalmologists for further evaluation of their DR condition. The referral process will specifically target patients suspected or known to have PDR, who may require vitrectomy. These patients will then be considered for potential enrolment in the study. Assignment of interventions: allocation Sequence generation {16a} SPIRIT guidance: Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign witinterventions. The allocation of participants in this study will be performed through a process of computer-generated random numbers. The enrolled participants will be randomly assigned to one of two groups: the vitrectomy combined with intravitreal dexamethasone implant group, and the vitrectomy-only group. The ratio of participants assigned to each group will be 1:1, without any additional stratification. To ensure the integrity of the randomization process, the randomized numbers will be generated by a computer and provided in a separate document. This document will remain inaccessible to individuals involved in patient enrollment or the performance of vitrectomy. By maintaining the confidentiality of the randomized number assignment, we aim to minimize any potential biases or influences on participant allocation. Concealment mechanism {16b} SPIRIT guidance: Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned. The randomization design will use permuted block sizes of 4 and 6 with the participant assignments placed in opaque, sealed, and serially numbered envelopes and individualized for each participant. Implementation {16c} SPIRIT guidance: Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions. The randomization schedule will be generated by the data analyst (ZM), who will deliver this document in a sealed envelope to the surgeon (LJP) responsible for assigning the participants to the two groups. Assignment of interventions: Blinding Who will be blinded {17a} SPIRIT guidance: Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how. In this randomized, blind controlled trial protocol, it is crucial to maintain blinding for both the participants and the data analyst after assignment to the intervention groups. To ensure participant blinding, measures will be taken to prevent participants from discerning their assigned treatment group. This may include the use of identical packaging or labeling for both interventions, as well as avoiding any explicit communication or disclosure regarding the treatment received. Similarly, the data analyst responsible for data analysis and outcome assessments will be kept blind to the treatment allocation. This can be achieved by withholding information regarding the assigned interventions in the data provided for analysis. Additionally, any identifying details that may inadvertently reveal the treatment group will be masked or removed from the dataset. However, it should be noted that the surgeon performing the vitrectomy and the ophthalmologists in charge of follow-up evaluations will not be blind to the interventions. Due to the nature of the study, the intravitreal dexamethasone implant used in one of the intervention groups can be visually identified in the vitreous during vitrectomy and in follow-up examinations. Therefore, blinding of the surgical team and the follow-up ophthalmologist is not feasible in this study. Procedure for unblinding if needed {17b} SPIRIT guidance: If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial. Unblinding of participants to their assigned interventions will be conducted under specific circumstances, following predefined criteria. The unblinding procedure will be implemented as outlined below: If a participant's overall health condition significantly worsens and poses a threat to their life, unblinding will be initiated to ensure appropriate medical management and intervention. In cases where the participant experiences elevated intraocular pressure (IOP) exceeding 30 mmHg, with suboptimal response to medication, unblinding will be considered. Unblinding may also occur if the participant develops intraocular inflammation, indicating the need for specialized treatment and care. The process of unblinding will be carefully conducted by authorized individuals who are not involved in the primary assessment or outcome evaluation. These individuals will have access to the allocation information, which will remain confidential throughout the study duration. If or emergency unblinding occurs in more than 20% of cases before the completion of the trial, it will be deemed a failure of the double-blind trial. Data collection and management Plans for assessment and collection of outcomes {18a} SPIRIT guidance: Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol. To ensure data quality, we employ various processes, including duplicate measurements and rigorous training of assessors. The data will be entered through a on-line web browser input form designed at JanDao Cloud platform. The Epidata EDC system will be used for data collection. Patient data will be documented by dedicated trial personnel and managed in the eCRF. All staff involved in the data collection process are to be qualified to access the research database. Our study utilizes specialized ophthalmic examination and surgical equipment, including standard devices for intraocular pressure measurement, visual acuity assessment, vitrectomy and OCT scans. All measurements strictly adhere to clinical trial protocols, ensuring data precision and accuracy for proliferative diabetic retinopathy vitrectomy procedures. The data entry forms are stored within the JianDao Cloud platform, where duly authorized researchers gain access through mobile phone number verification. Plans to promote participant retention and complete follow-up {18b} SPIRIT guidance: Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols. To ensure participant retention and data completeness, we will emphasize the importance of scheduled follow-up appointments through education. During clinical encounters, we'll discuss and schedule follow-up visits with participants and their families. Additionally, a designated staff member will perform telephone follow-ups for participants exceeding a two-week follow-up gap. To address potential non-compliance or attrition, we've outlined specific outcome data collection. This streamlined approach aims to maximize research integrity and data collection even in cases of participant non-compliance or attrition. One of the following outcome data will be collected for participants who discontinue the study: 1) Patients completing a 6-month follow-up; 2) Patients undergoing secondary surgery due to retinal detachment with non-repositioning or non-absorption of vitreous hemorrhage; 3) Patients undergoing glaucoma surgery due to inadequate control with ocular hypotensive medications (including secondary to fillers, uncontrolled neovascular glaucoma, medication-induced); 4) Incidence of intraocular inflammation; 5) Surgical removal of implant dislocated into the anterior chamber; 6) Deterioration of general health preventing follow-up; 7) Visual loss or patient discontinuation of treatment during follow-up. Monthly reviews of clinical research issues are conducted, categorized by deviation severity. All protocol deviations are documented in a Protocol Deviation Report, detailing discovery time, event timelines, reasons, and corrective actions. Severe deviations affecting subject rights, safety, or data integrity are reported to regulatory authorities and ethics committees, outlined in the research plan. In blinded studies, protocol deviations are managed separately for blinded and unblinded teams, with specialized unblinded team review. Severe deviations may lead to data exclusion from specific analysis populations. Mild deviations, not classified as severe, won't trigger data exclusion unless they recur and become severe. Data management {19} SPIRIT guidance: Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol. Data collection entails a meticulous process characterized by the independent entry of data by two trained staff members. Subsequently, Epidata is utilized to assess data consistency. In cases of inconsistency, a third staff is involved for data verification and validation. This rigorous protocol ensures data integrity, aligning with the highest standards of research precision. The principal investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported. Confidentiality {27} SPIRIT guidance: How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial. We prioritize participant data confidentiality throughout the trial, in compliance with national data protection laws and WHO Good Clinical Practice guidelines. All patient data, including case report forms, is securely managed to maintain privacy during and after the trial. Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33} SPIRIT guidance: Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable. N/a Statistical methods Statistical methods for primary and secondary outcomes {20a} SPIRIT guidance: Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol. This study used R for statistical analysis of data. A P-value < 0,05 will be considered as statistically significant. Visual acuity and OCT measurements were analyzed using repeated measures analysis of variance with two-tailed tests; Rates of visual improvement, visual decline, the occurrence of postoperative vitreous hemorrhage, elevated intraocular pressure and postoperative retinal detachment were analyzed using chi-square tests with two-tailed tests; Descriptive statistics: Normal continuous data were described using mean and standard deviation; non-normally distributed continuous data were described using median and quartiles; categorical variables were described using proportions and rates; Grouping variables: For continuous data, t-tests or rank-sum tests were used; for categorical variables, chi-square tests or Fisher's exact tests were used; Analysis of risk factors for poor visual prognosis, neovascular glaucoma development, and postoperative vitreous hemorrhage occurrence was conducted using logistic regression analysis. Interim analyses {21b} SPIRIT guidance: Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial. Interim analysis will be conducted after 1 year of study initiation or when 50% of the medical records have been collected. The interim analysis will be carried out by PI and members who are in charge of statistic analysis, who will then decide whether to terminate the trial based on the results. Methods for additional analyses (e.g. subgroup analyses) {20b} SPIRIT guidance: Methods for any additional analyses (eg, subgroup and adjusted analyses). There are no planned subgroup analyses. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c} SPIRIT guidance: Definition of analysis population relating to protocol non-adherence (eg, as randomized analysis), and any statistical methods to handle missing data (eg, multiple imputation). Descriptive statistical analysis was conducted on the population of enrolled participants who completed the 12-week follow-up. Participants who did not adhere to the study protocol were subject to data exclusion, which was determined by the data statistician based on individual patient circumstances. Lost-to-follow-up data were analyzed by the data statistician based on individual patient circumstances using a direct exclusion method. Plans to give access to the full protocol, participant level-data and statistical code {31c} SPIRIT guidance: Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code. Access to the protocol and the results will be granted on reasonable request to the authors. Oversight and monitoring Composition of the coordinating centre and trial steering committee {5d} Trials guidance: Provide information on the composition, roles and responsibilities of the coordinating centre and trial steering committee and all groups providing day to day support for the trial. There will always be a group running the trial day-to-day and providing organisational support and knowing how often they will meet, plus information on other committees providing oversight such as a Trial Steering Committee, and how often they will meet over the course of the trial, is what we need for item 5d. We do not need names of staff. SPIRIT guidance: Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee). This is a single center research. This investigator-initiated trial will be coordinated by the Department of Ophthalmology in Beijing Tongren eye center. The evaluation of the study progress will be done monthly. Composition of the data monitoring committee, its role and reporting structure {21a} SPIRIT guidance: Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed. No special data monitoring is needed for this single-center research. Adverse event reporting and harms {22} SPIRIT guidance: Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct. Any adverse medical events occurring from the patient's signing of the informed consent form to their last follow-up, whether causally related to the experimental drug, are considered adverse events. These events are reported and managed following hospital protocols, and records include event timing, severity, duration, interventions, and outcomes. Adverse events are defined as those resulting in death, life-threatening situations, hospitalization, extended hospital stays, or permanent/severe disability/loss of function. After an adverse event, it is reported to relevant departments, and management follows the guidance of department consultations, adhering to hospital protocols. Frequency and plans for auditing trial conduct {23} SPIRIT guidance: Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor. The trial will be audited by the ethics committee of Beijing Tongren hospital on a yearly basis. Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25} SPIRIT guidance: Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators). We will communicate the important protocol modifications with ethics committee for approval. The approved changes of the protocol will be discussed with investigators and trail registries. Dissemination plans {31a} SPIRIT guidance: Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions. We plan to communicate trail results to participants, healthcare professionals and public via publication, reporting in results databases. Discussion Trials guidance: This should include a discussion of any practical or operational issues involved in performing the study and any issues not covered in other sections. This study is a prospective randomized controlled trial, and there is no similar research available on the efficacy of intravitreal dexamethasone combined with vitrectomy in the treatment of PDR. Prior studies have confirmed that the incidence of macular edema following pars plana vitrectomy in PDR patients is high, making it one of the primary factors affecting visual prognosis [4]. Therefore, this study aims to shed light on the role of intravitreal dexamethasone in alleviating macular edema and improving visual outcomes in PDR patients after vitrectomy. A key issue in this research lies in the execution of blinding. The dexamethasone drug used in the study is white in colour. To minimize any potential influence on the surgeon's decisions during vitrectomy, we chose to unmask and administer the injection at the time of closing the incisions. During follow-up, the implant may be located either in the vitreous cavity or anterior to the retina and may be visible. Therefore, the informed consent documents for patients explicitly state that patients should not be concerned about the presence or absence of linear shadows post-surgery and should adhere to the scheduled follow-up visits. However, for the physicians responsible for postoperative examinations, indirect ophthalmoscopy fundus examination may reveal the presence of the implant in the vitreous cavity. Therefore, blinding is not feasible for postoperative follow-up doctors, surgeons at the end of the surgery, and patients who perceive distinctive dark shadows in their vision. However, blinding can be maintained for the surgeon preoperatively, patients preoperatively, individuals involved in data collection and analysis, and patients without clear distinctive dark shadows postoperatively. As a result, this study is a clinical research utilizing blinding in a single-blind, randomized controlled trial manner and cannot achieve double-blinding. Due to the majority of patients being non-local, postoperative follow-up poses some challenges. We have employed strategies such as preoperative education on the importance of post-vitrectomy follow-up, pre-scheduled appointments, and the use of follow-up forms to remind both the follow-up doctors and patients to ensure timely completion of follow-up visits. During the follow-up process, a designated person is responsible for promptly identifying patients who have not attended follow-up visits for more than two weeks. We will communicate with these patients through phone calls to encourage them to return for follow-up, and for those unable to visit, PI is responsible for conducting telephone tracking as outlined in the pre-designed tracking protocol and rearranging the missed follow-up for the patients. In the statistical analysis, vision and OCT thickness measurements are subjected to repeated-measures analysis of variance. To ensure that the results are minimally affected by measurement variations across different devices, we employ the same measurement personnel for corrected vision measurement and the same instrument for OCT retinal thickness measurement. To ensure an adequate sample size for the efficacy analysis of diabetic retinopathy macular edema, we estimated the sample size based on reported rates from prior literature and our pre-experimental results of postoperative macular edema incidence, adding a 10–15% of dropout rate of the participants during the 24-week follow-up. Trial status Trials guidance: Authors should report the protocol version number and date, the date recruitment began, and the approximate date when recruitment will be completed. The version of the protocol is 20220909. The date of the approval of the protocol is September 29th, 2022. The recruitment began at November 23th, 2022, it will be completed at December 4th, 2023. Abbreviations Trials guidance: If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations should be provided. CRT central retinal thickness DME diabetic macular edema DR diabetic retinopathy FVM fibrovascular vascular membranes IVR intravitreal ranibizumab PDR proliferative diabetic retinopathy PI primary investigator OCT optic coherence tomography VH vitreous hemorrhage Declarations Acknowledgements Trials guidance: Please acknowledge anyone who contributed towards the article who does not meet the criteria for authorship including anyone who provided professional writing services or materials. Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section. See our editorial policies for a full explanation of acknowledgements and authorship criteria. If you do not have anyone to acknowledge, please write "Not applicable" in this section. We thank the technicians who check the corrected visual acuity and OCT CRT measurement, the fellow resident who will oversee the patients when they undergo vitrectomy, the nurses who will oversee the education of PDR during the patients stay in the hospital. All their work will contribute to the accuracy of the data and good compliance of the PDR patients. Group authorship (for manuscripts involving a collaboration group): if you would like the names of the individual members of a collaboration Group to be searchable through their individual PubMed records, please ensure that the title of the collaboration Group is included on the title page and in the submission system and also include collaborating author names as the last paragraph of the “Acknowledgements” section. Please add authors in the format First Name, Middle initial(s) (optional), Last Name. You can add institution or country information for each author if you wish, but this should be consistent across all authors. Please note that individual names may not be present in the PubMed record at the time a published article is initially included in PubMed as it takes PubMed additional time to code this information. Not applicable. Authors’ contributions {31b} SPIRIT guidance: [31b] - Authorship eligibility guidelines and any intended use of professional writers. Trials guidance: The individual contributions of authors to the manuscript should be specified in this section. Guidance and criteria for authorship can be found in our editorial policies. Please use initials to refer to each author's contribution in this section, for example: "AB is the Chief Investigator; she conceived the study, led the proposal and protocol development. CD contributed to study design and to development of the proposal. EF was the lead trial methodologist. All authors read and approved the final manuscript." Jipeng Li is the primary investigator, he led the proposal and protocol development. Meng Zhao contributed to study design and to development of the proposal, she was the trail methodologist. Jun Xu is in charge of disclose the blind and the follow-up of the patients. Lin Liu is in charge of scheduling the visiting of the patients, entering data and store the record sheet and education about the follow-up. Aman Chandra is in charge of study design, supervision of the study data collection, revising the manuscript. Funding {4} SPIRIT guidance: Sources and types of financial, material, and other support. Trials guidance: All sources of funding for the research reported should be declared. You will be required to include a copy of the original funding document and an English translation of this document as an additional file on submission, which will be checked against this declaration. The role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript should be declared. No funding. Availability of data and materials {29} SPIRIT guidance: Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators. Trials guidance: Please do not include any baseline or pilot data in your study protocol. The Editorial Office will ask you to remove this if it is included. Please declare here who will have access to the final trial dataset and disclose contractual agreements that limit such access for investigators. In this study, only members of the research team will have access to the data. Ethics approval and consent to participate {24} SPIRIT guidance: Plans for seeking research ethics committee/institutional review board (REC/IRB) approval. Trials guidance: Trials do not consider study protocols for studies without ethical approval. You will be required to provide a copy of the original ethical approval document and an English translation of this document as an additional file on submission, which will be checked against this declaration. The name of the ethics committee that approved the study and the committee’s reference number (if applicable) should be declared. Details of authors’ intentions to obtain consent to participate in the study from participants (or their parent or legal guardian in the case of children under 16) should be declared. “eg. ABC Ethical Review Board ABC123456. Written, informed consent to participate will be obtained from all participants” The study followed the tenets of the Declaration of Helsinki and the protocol and was approved by the Institutional Review Board of Beijing Tongren Hospital (TREC2022-KY063) at 30th August 2022. Patients were required to sign an informed consent form, and written informed consent was obtained from each participant. Consent for publication {32} SPIRIT guidance: Model consent form and other related documentation given to participants and authorised surrogates. Trials guidance: Please do not include any baseline or pilot data in your study protocol. The Editorial Office will ask you to remove this if it is included. If you have included any details, images or videos relating to an individual person, written informed consent for the publication of these details must be obtained from that person (or their parent or legal guardian in the case of children under 18) and declared in this section. Please also state whether you will be willing to provide a model consent form on request. If this section does not apply, please state “Not applicable”. Not applicable. Competing interests {28} SPIRIT guidance: Financial and other competing interests for principal investigators for the overall trial and each study site. Trials guidance: All financial and non-financial competing interests must be declared in this section. See our editorial policies for a full explanation of competing interests. If you are unsure whether you or any of your co-authors have a competing interest please contact the editorial office. Please use the authors initials to refer to each authors' competing interests in this section. If you do not have any competing interests, please state: "The authors declare that they have no competing interests" in this section. The authors declare that they have no competing interests. Authors ’ information (optional) Trials guidance: This section is optional. You may choose to use this section to include any relevant information about the author(s) that may aid the reader's interpretation of the article, and understand the standpoint of the author(s). This may include details about the authors' qualifications, current positions they hold at institutions or societies, or any other relevant background information. Please refer to authors using their initials. Note this section should not be used to describe any competing interests. References Flaxman, Bourne, Resnikoff et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health 2017;5: e1221-e1234, doi:10.1016/s2214-109x(17)30393-5. Liu, Wu, Liu et al. Prevalence of diabetic retinopathy in mainland China: a meta-analysis. PloS one 2012;7: e45264-e45264, doi:10.1371/journal.pone.0045264. Stewart, Browning & Landers. Current management of diabetic tractional retinal detachments. Indian J Ophthalmol 2018;66: 1751-1762, doi:10.4103/ijo.IJO_1217_18. Schreur, Brouwers, Van Huet et al. Long-term outcomes of vitrectomy for proliferative diabetic retinopathy. Acta Ophthalmol 2021;99: 83-89, doi:10.1111/aos.14482. Yau, Silva, Arrigg et al. Postoperative Complications of Pars Plana Vitrectomy for Diabetic Retinal Disease. Seminars in ophthalmology 2018;33: 126-133, doi:10.1080/08820538.2017.1353832. Rittiphairoj, Mir, Li et al. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 2020;11: Cd005656, doi:10.1002/14651858.CD005656.pub3. Puliafito, Cousins, Bacharach et al. Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina 2016;47: S4-s15, doi:10.3928/23258160-20160224-01. Ehlers, Yeh, Maguire et al. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology 2022;129: 88-99, doi:10.1016/j.ophtha.2021.07.009. Boyer, Faber, Gupta et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31: 915-923, doi:10.1097/IAE.0b013e318206d18c. Altun, Kanar, Aki et al. Effectiveness and Safety of Coadministration of Intravitreal Dexamethasone Implant and Silicone Oil Endotamponade for Proliferative Diabetic Retinopathy with Tractional Diabetic Macular Edema. J Ocul Pharmacol Ther 2021;37: 131-137, doi:10.1089/jop.2020.0079. Someya, Takayama, Takeuchi et al. Outcomes of 25-Gauge Vitrectomy for Tractional and Nontractional Diabetic Macular Edema with Proliferative Diabetic Retinopathy. J Ophthalmol 2019;2019: 5304524, doi:10.1155/2019/5304524. Cite Share Download PDF Status: Published Journal Publication published 12 Feb, 2025 Read the published version in Trials → Version 1 posted Reviewers agreed at journal 10 Apr, 2024 Reviewers invited by journal 29 Mar, 2024 Editor assigned by journal 15 Feb, 2024 First submitted to journal 14 Dec, 2023 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3622174","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":285358093,"identity":"ff5642cd-9629-4f10-b62e-c7eac9ca34f0","order_by":0,"name":"萌 赵","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABCElEQVRIiWNgGAWjYDACCTjrABAbMDDwMzA2kKhFsoF4LVBgcICAu+RnNz98dKPijl0D4+HHn24U3JEzPn+47cEPBjs5XRyWMc45Zmycc+ZZcgPDMTPpHINnxmY3EtsNexiSjc1wWMcskWAmndt2OBnoFzPmHIPDidtuMLZJ8DAcSNyGQwubRPo36dx/IC3HP38Gaqnf3H+wTfIPHi08EjlAWxoO2zEwnDEAOuxwggFDYps0PlskJHKKjXOOHU4AaikDaTGccQOoRcYAt1/kZ6RvfJxTc9ieQeL45s85fw7L8/cffyb5psJODpcWGEjcfwNFhQF+5SBgz8DfQFjVKBgFo2AUjEwAAG2NYGGw2iTgAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0002-3705-3056","institution":"Beijing Tongren Eye Center","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"萌","middleName":"","lastName":"赵","suffix":""},{"id":285358094,"identity":"8f404d97-33ae-4bf4-903b-f2f9517a98d1","order_by":1,"name":"Aman Chandra","email":"","orcid":"","institution":"South Essex Partnership NHS Foundation Trust: Essex Partnership University NHS Foundation Trust","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Aman","middleName":"","lastName":"Chandra","suffix":""},{"id":285358095,"identity":"8411e8ec-0c03-4f3b-ad84-dd25aa2c42e0","order_by":2,"name":"Jun Xu","email":"","orcid":"","institution":"Beijing Tongren Eye Center","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jun","middleName":"","lastName":"Xu","suffix":""},{"id":285358096,"identity":"046e356c-e0e3-4ff6-b308-37f71757596a","order_by":3,"name":"Lin Liu","email":"","orcid":"","institution":"Beijing Tongren Eye Center","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lin","middleName":"","lastName":"Liu","suffix":""},{"id":285358097,"identity":"53fc8413-94d6-42ee-976c-8c5186ae986d","order_by":4,"name":"Jipeng Li","email":"","orcid":"","institution":"Beijing Tongren Eye Center","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jipeng","middleName":"","lastName":"Li","suffix":""}],"badges":[],"createdAt":"2023-11-16 19:57:25","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3622174/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3622174/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s13063-025-08758-1","type":"published","date":"2025-02-12T15:57:26+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":54036169,"identity":"08c5360a-ced5-4e1f-b1ae-ab8700857803","added_by":"auto","created_at":"2024-04-03 17:01:50","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":50302,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version.\u003c/p\u003e","description":"","filename":"Picture1.png","url":"https://assets-eu.researchsquare.com/files/rs-3622174/v1/d2c87b776becb3733d359f41.png"},{"id":76487675,"identity":"f2bc671a-ca69-4101-a289-70131665d878","added_by":"auto","created_at":"2025-02-17 16:11:01","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1545265,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3622174/v1/3b975506-e705-47d3-b191-fc2155cbea89.pdf"}],"financialInterests":"","formattedTitle":"The effectiveness of vitrectomy co-adjuvant intravitreal dexamethasone implant on visual outcome in patients with proliferative diabetic retinopathy: study protocol for a prospective randomized controlled trail","fulltext":[{"header":"Administrative Information","content":"\u003cp\u003eNote: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/).\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"639\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11580594679186%\" valign=\"top\"\u003e\n \u003cp\u003eTitle\u0026nbsp;{1}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"65.88419405320813%\" valign=\"top\"\u003e\n \u003cp\u003eThe effectiveness of vitrectomy co-adjuvant intravitreal dexamethasone implant on visual outcome in patients with proliferative diabetic retinopathy: study protocol for a prospective randomized controlled trail.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11580594679186%\" valign=\"top\"\u003e\n \u003cp\u003eTrial registration {2a and 2b}.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"65.88419405320813%\" valign=\"top\"\u003e\n \u003cp\u003eChiCTR2200059760, \u0026nbsp;Chinese Clinical Trial Registry\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11580594679186%\" valign=\"top\"\u003e\n \u003cp\u003eProtocol version {3}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"65.88419405320813%\" valign=\"top\"\u003e\n \u003cp\u003e2022-9-9, Version 20220909\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11580594679186%\" valign=\"top\"\u003e\n \u003cp\u003eFunding {4}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"65.88419405320813%\" valign=\"top\"\u003e\n \u003cp\u003eThis study was not supported by any funding.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11580594679186%\" valign=\"top\"\u003e\n \u003cp\u003eAuthor details {5a}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"65.88419405320813%\" valign=\"top\"\u003e\n \u003cp\u003eJipeng Li1, \u0026nbsp; \u0026nbsp; Aman Chandra2, Jun Xu1, Lin Liu 1, Meng Zhao1\u003c/p\u003e\n \u003cp\u003e1 Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University. No1. Dongjiaominxiang street, Dongcheng District, Beijing,100730, China.\u003c/p\u003e\n \u003cp\u003e2 Mid \u0026amp; South Essex NHS Foundation Trust (Southend University Hospital) Prittlewell Chase Essex SS00RY, UK; Anglia Ruskin University, Cambridge, UK.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11580594679186%\" valign=\"top\"\u003e\n \u003cp\u003eName and contact information for the trial sponsor {5b}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"65.88419405320813%\" valign=\"top\"\u003e\n \u003cp\u003ePrimary investigator who initiate the research: Jipeng Li, [email protected]\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"34.11580594679186%\" valign=\"top\"\u003e\n \u003cp\u003eRole of sponsor {5c}\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"65.88419405320813%\" valign=\"top\"\u003e\n \u003cp\u003eThe sponsor play a role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"},{"header":"Introduction","content":"\u003cp\u003e\u003cstrong\u003eBackground and rationale {6a}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention.\u003c/p\u003e\n\u003cp\u003eProliferative diabetic retinopathy (PDR) is one of the major diseases threatening the vision of the working population[1] . China has a high prevalence of diabetes, and the incidence of diabetes is rapidly increasing[2]. When PDR progresses to the stage of tractional retinal detachment or recurrent vitreous hemorrhage (VH), vitrectomy \u0026nbsp;is required to salvage the remaining vision[3] . However, a long-term follow-up study involving 217 PDR patients who underwent vitrectomy showed that the rates of low vision at 1 year, 5 years, and 10 years after surgery were 24%, 31%, and 39%, respectively. Most complications occurred within the first year after surgery, with the top three being elevated intraocular pressure (37%), macular edema (29%), and retinal detachment (12%)[4] . Moreover, there is often a certain degree of intraocular inflammatory response after vitrectomy surgery[5], which can lead to macular edema, vitreous cavity proliferative changes, affecting postoperative visual recovery, and possibly necessitating further surgery. Diabetic patients often have complex systemic abnormalities，which limits systemic steroid as \u003cs\u003ea\u003c/s\u003e routine postoperative anti-inflammatory treatment.\u003c/p\u003e\n\u003cp\u003eIntraocular dexamethasone sustained-release system, administered via a minimally invasive injection, has emerged as a delivery route for ocular therapeutics and has found widespread application in diabetic macular edema (DME) [6] . It has been considered both effective and safe [7,8]. A prospective study involving patients with refractory DME following vitrectomy (55 patients over 26 weeks) demonstrated that intravitreal injection of dexamethasone sustained-release system after vitrectomy is a safe and effective treatment modality [9]. Earlier small-scale clinical trials (23 patients followed for 6 months) have shown that combining vitrectomy in diabetic patients with intravitreal dexamethasone sustained-release system injection and silicone oil tamponade helps alleviate tractional macular edema and reduces the need for postoperative intravitreal injections of other anti-inflammatory agents (such as anti-vascular endothelial growth factor agents), and this combined treatment approach has been proven to be safe during follow-up [10]. \u0026nbsp; However, the severity of PDR was not addressed in these aforementioned studies, and there is a scarcity of case reports on PDR cases involving tractional retinal detachment in the macular area. Limited reports are available for severe PDR cases that did not undergo preoperative retinal laser therapy. Therefore, there exists a research gap in the observation of patients with severe, untreated PDR. These patients often require complex surgical interventions due to extensive peripheral retinal detachments, which include combined cataract surgery, intraoperative pan-retinal photocoagulation, and postoperative gas tamponade, thereby increasing the likelihood of postoperative inflammatory reactions.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eObjectives {7}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Specific objectives or hypotheses.\u003c/p\u003e\n\u003cp\u003eIn China, many diabetic patients experience untreated progressive PDR lesions. These patients present with recurrent vitreous hemorrhage and tractional retinal detachment involving the macula at the initial consultation, with a lack of adequate previous photocoagulation or intravitreal anti-VEGF treatments. Such patients often require extensive intraoperative laser therapy and intraocular tamponade, leading to potentially heightened postoperative inflammatory responses. Our study aims to address the limitations of previous research by collecting a more diverse group of complex PDR patients. This will allow for a more comprehensive evaluation of the effectiveness and safety of this medication in the context of vitrectomy for progressive DR.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTherefore, this study aims to conduct a prospective randomized controlled trial on patients with untreated PDR requiring vitrectomy. The study aims to observe the differences between vitrectomy combined with intravitreal dexamethasone sustained-release implant system injection and simple vitrectomy in terms of postoperative inflammatory reactions, postoperative visual improvement, resolution of DME, as well as common postoperative complications like postoperative VH and intraocular pressure fluctuations. The goal is to understand the efficacy and safety of vitrectomy combined with intravitreal dexamethasone sustained-release implant system in patients with PDR.\u003c/p\u003e\n\u003cp\u003eBased on previous research findings, the incidence of postoperative macular edema in PDR is 29%, with 18% occurring within one year post-surgery [4]. In PDR patients who had pre-existing macular edema before surgery, the rate of resolution of macular edema after vitrectomy is only 22.9-29% [11]. We hypothesize that by combining intravitreal injection of dexamethasone sustained-release system with vitrectomy, we can reduce the incidence of postoperative macular edema and improve the resolution of pre-existing macular edema, thereby enhancing visual function.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTrial design {8}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory).\u003c/p\u003e\n\u003cp\u003eA single-blind randomized control trial will be conducted to compare the effects of vitrectomy combined with intravitreal dexamethasone implant with vitrectomy (Fig. 1). The study will be conducted for 24 weeks (6 months), and this period will include a 24-week follow-up period with primary outcomes measured at baseline, 4, 8, 12 weeks and secondary outcomes measured at baseline, 4, 8,12,24 weeks. The allocation ratio is set at 1. The framework is exploratory.\u003c/p\u003e"},{"header":"Methods: Participants, interventions and outcomes","content":"\u003cp\u003e\u003cstrong\u003eStudy setting {9}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBeijing Tongren eye center, an tertiary academic hospital, will serve as the primary site for the study. The data will be collected at the same center.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEligibility criteria {10}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists).\u003c/p\u003e\n\u003cp\u003eInclusion Criteria:\u003c/p\u003e\n\u003col\u003e\n \u003cli\u003ePatients with PDR will be included in the study if they meet one of the following three criteria: 1) presence of tractional retinal detachment involving the macula or an area adjacent to the macula, as confirmed by clinical examination; 2) presence of recurrent or non-absorbing vitreous haemorrhages; 3) simultaneous presence of vitreous haemorrhage and tractional retinal detachment confirmed by B-scan ultrasound examination when the fundus was obscured by vitreous haemorrhage.\u0026nbsp;\u003cbr\u003eAdditional inclusion criteria are as follows:\u003c/li\u003e\n \u003cli\u003eAge between 18 and 70 years.\u003c/li\u003e\n \u003cli\u003eWillingness to participate in the study and comply with scheduled follow-up visits.\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003eExclusion criteria:\u003c/p\u003e\n\u003cp\u003eParticipants will be excluded from the study if any of the following conditions are reported:\u003c/p\u003e\n\u003col\u003e\n \u003cli\u003ePresence of severe uncontrolled systemic abnormalities that contraindicated to vitrectomy surgery;\u003c/li\u003e\n \u003cli\u003eRecent (\u0026lt;3month) administration of other intravitreal dexamethasone implant;\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eHistory of glaucoma;\u003c/li\u003e\n \u003cli\u003eHistory of conditions that may cause macular edema, such as uveitis or retinal vein occlusion;\u003c/li\u003e\n \u003cli\u003eHistory of previous vitrectomy;\u003c/li\u003e\n \u003cli\u003eIntraoperative identification of vitreous hemorrhage not caused by PDR;\u003c/li\u003e\n \u003cli\u003eInability of the patient to complete the scheduled follow-up visits\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u003cstrong\u003eWho will take informed consent? {26a}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32).\u003c/p\u003e\n\u003cp\u003eThe primary investigator will obtain informed consent from the potential trial participants.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdditional consent provisions for collection and use of participant data and biological specimens {26b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable.\u003c/p\u003e\n\u003cp\u003eNo secondary participant information or data will be collected, nor any biological specimens will be collected .\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInterventions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eExplanation for the choice of comparators {6b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Explanation for choice of comparators.\u003c/p\u003e\n\u003cp\u003eThe two comparators in this study are the vitrectomy combined with intravitreal dexamethasone implant group and the vitrectomy group (control group). These comparators were selected to evaluate the impact of vitrectomy combined with intravitreal dexamethasone implant on the visual outcomes and macular morphology of individuals with PDR during the 24-week post-vitrectomy period. By comparing these outcomes with those of individuals who underwent vitrectomy alone, the study aims to assess the effectiveness and safety of the intervention. The inclusion of a control group receiving vitrectomy alone allows for a comprehensive and clinically relevant evaluation of the intervention\u0026apos;s effects in comparison to established treatment options. This approach ensures that the study findings can be extrapolated to real-world clinical practice, facilitating evidence-based decision-making in the management of PDR.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eIntervention description {11a}\u003c/strong\u003e\u003cbr\u003e\u0026nbsp;SPIRIT guidance: Interventions for each group with sufficient detail to allow replication, including how and when they will be administered.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eVitrectomy:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe patients underwent retrobulbar or general anesthesia. All patients underwent 23/25 gauge 3-port pars plana vitrectomy (PPV) using the Constellation Vision System (Alcon, Fort Worth, Texas, USA). Patients with active fibrovascular epiretinal proliferative membranes (FVMs) or severe vitreous hemorrhage (VH) obscuring the fundus received intravitreal ranibizumab (IVR) within seven days prior to vitrectomy, and the pre-vitrectomy IVR administration was documented. Following core vitrectomy, the presence of FVM, macular-involving tractional retinal detachment (TRD), and photocoagulation scars were documented. Triamcinolone acetonide-assisted vitrectomy was performed, releasing anterior-posterior vitreoretinal traction and inducing posterior vitreous detachment. Dissection, segmentation, delamination of FVM, endodiathermy, drainage of subretinal fluid, retinectomy, and intraocular tamponade were performed as needed for each patient. Peripheral vitrectomy with scleral indentation and endolaser photocoagulation were performed for all patients. Intraoperative bleeding was managed using techniques such as intraocular pressure elevation, perfluorocarbon liquids, and endodiathermy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eIntravitreal dexamethasone implant:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAt the end of vitrectomy and before the closure of sclera incision, the dexamethasone implant was injected into the vitreous from the incision.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eVitrectomy combined with intravitreal dexamethasone implant group:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePatients in this group will receive vitrectomy and an intravitreal dexamethasone implant at the end of vitrectomy.\u003c/p\u003e\n\u003cp\u003eVitrectomy group:\u003c/p\u003e\n\u003cp\u003ePatients in this group will receive vitrectomy only.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCriteria for discontinuing or modifying allocated interventions {11b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease).\u003c/p\u003e\n\u003cp\u003eDiscontinuation Criteria:\u003c/p\u003e\n\u003cp\u003eObservation endpoints for study discontinuation were defined as follows: 1) Patient completion of the 6-month follow-up period; 2) Patient requiring a second surgery for non-attached retina or non-absorption of vitreous hemorrhage; 3) Patient undergoing glaucoma surgery due to poor control of intraocular pressure with medication (including secondary to intraocular tamponade, uncontrolled neovascular glaucoma, or medication-induced); 4) Occurrence of uncontrolled intraocular inflammation; 5) Surgical removal of dislodged implant from the anterior chamber; 6) Deterioration of the patient\u0026apos;s overall systemic condition preventing further follow-up; 7) Loss of visual acuity during the follow-up period or patient withdrawal from the treatment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStrategies to improve adherence to interventions {11c}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests).\u003c/p\u003e\n\u003cp\u003eAll participants will receive preoperative education on PDR from the surgeon, emphasizing the significance of regular follow-up visits. During each follow-up appointment, scheduled plans for the next six months will be discussed individually with the participants, taking into consideration their availability and schedules. In the event that participants fail to adhere to the monthly follow-up schedule, the Principal Investigator (PI) will proactively contact the participant to ascertain the reasons for delayed presentation and investigate any underlying factors and rearrange the new schedule for follow-up if the participant could continue the previous follow-up plan.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRelevant concomitant care permitted or prohibited during the trial {11d}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Relevant concomitant care and interventions that are permitted or prohibited during the trial.\u003c/p\u003e\n\u003cp\u003eNo concomitant care and intervention requirements are either permitted or prohibited during the trial. The participants will be asked to maintain their medication dosage and any mandatory medical care or aid that they are receiving during the intervention period.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProvisions for post-trial care {30}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation.\u003c/p\u003e\n\u003cp\u003eN/a.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOutcomes {12}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended.\u003c/p\u003e\n\u003cp\u003eAll outcome measures will be conducted by the researchers, binding to group allocation, at baseline, at 4,8,12,24- week follow-up after vitrectomy.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDemographics, including age; gender; preoperative characteristics, including DM duration and DM medication, and the history of diabetes-related complications, including stroke, coronary artery disease (CAD), congenital heart failure, diabetic foot and chronic kidney disease, and hypertension; anticoagulation or antiplatelet medications; and ocular characteristics, including the history of previous photocoagulation, cataract phacoemulsification extraction, IV anti-VEGF agents, visual symptom duration will be collected.\u003c/p\u003e\n\u003cp\u003eAll the patients will go through a comprehensive ocular examination after enrollment, including corrected visual acuity (VA) tested by a Snellen decimal VA chart, intraocular pressure test by non-contact tonometer, silt lamp examination to evaluate lens status and the presence of iris neovascularization and neovascular glaucoma, binocular indirect ophthalmoscopy examination to evaluate severity of VH and FVP, B-scan ultrasound examination to identify retinal detachment and OCT scan to evaluate macular morphology if possible.\u003c/p\u003e\n\u003cp\u003ePrimary outcome measures:\u003c/p\u003e\n\u003cp\u003eThe primary outcome measures in this research protocol include corrected visual acuity at 12 weeks post-treatment. Baseline visual acuity and corrected visual acuity at 4, 8, and 12 weeks post-treatment will be measured using the LogMAR visual acuity chart. \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe assessment of corrected visual acuity will not involve the collection of biological samples. Corrected visual acuity serves as a universally recognized efficacy indicator for surgical treatment of PDR eyes.\u003c/p\u003e\n\u003cp\u003eSecondary outcome measures:\u003c/p\u003e\n\u003cp\u003eThe secondary outcome measures in this research protocol encompass the following parameters:\u003c/p\u003e\n\u003col\u003e\n \u003cli\u003eRetinal reattachment rate at 24 weeks post-vitrectomy evaluated by fundus examination using indirect binocular ophthalmoscopy.\u003c/li\u003e\n \u003cli\u003eCentral macular thickness on OCT at 12- and 24-weeks post-vitrectomy.\u003c/li\u003e\n \u003cli\u003eIncidence of intraocular pressure elevation recorded at 12- and 24-weeks post-vitrectomy.\u003c/li\u003e\n \u003cli\u003eIncidence of occurrence of postoperative vitreous hemorrhage during the 24-week followup after vitrectomy evaluated by fundus examination using indirect binocular ophthalmoscopy.\u003c/li\u003e\n \u003cli\u003eOccurrence of subsequent cataract surgery in the following 24 weeks after vitrectomy.\u003c/li\u003e\n \u003cli\u003eIncidence of choroidal detachment within 4 weeks post-vitrectomy.\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003eAmong these measures, the retinal reattachment rate, incidence of postoperative vitreous hemorrhage, and occurrence of choroidal detachment are recognized efficacy indicators for surgical treatment. The rates of intraocular pressure elevation and subsequent cataract surgery serve as safety indicators for intraocular implantation. Central macular thickness on OCT is a widely accepted metric for evaluating macular morphology.\u003c/p\u003e\n\u003cp\u003eThe inclusion of these secondary outcome measures allows for a comprehensive evaluation of treatment efficacy, safety, and specific macular morphology changes associated with the intervention.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eParticipant timeline {13}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see figure at http://www.spirit-statement.org/publications-downloads/).\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"684\" height=\"856\"\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSample size {14}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations.\u003c/p\u003e\n\u003cp\u003eThe estimated number of participants to achieve the study\u0026rsquo;s objectives is 39 per group, calculated to attain a 93% statistical power in the difference between two means of the independent variables for testing hypotheses with an alpha level of 5% and a minimal clinical important difference (MCID) of 1.13. This estimation is based on the calculation of the minimal clinical important difference that was determined based on the values obtained in past published studies[4]\u0026nbsp;[9]\u0026nbsp;[10]. Considering a 10-15% of dropout rate of the participants during the 24-week follow-up, the estimated number f participants is 50 per group.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRecruitment {15}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Strategies for achieving adequate participant enrolment to reach target sample size.\u003c/p\u003e\n\u003cp\u003eParticipants with PDR requiring vitrectomy will be recruited from the outpatients\u0026apos; clinics at Tongren Eye Center between October 2022 and October 2024 (The duration of patient recruitment is two years from the date of approval). The recruitment process will involve two sources, as outlined below:\u003c/p\u003e\n\u003cp\u003e1. Three retinal specialists, who collectively encounter over 60 PDR patients on a weekly basis, will oversee the recruitment of participants. These specialists will identify and approach eligible individuals for potential inclusion in the study.\u003c/p\u003e\n\u003cp\u003e2. Diabetic patients present at physicians at Tongren Hospital will be referred to the participated ophthalmologists for further evaluation of their DR condition. The referral process will specifically target patients suspected or known to have PDR, who may require vitrectomy. These patients will then be considered for potential enrolment in the study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAssignment of interventions: allocation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSequence generation {16a}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign witinterventions.\u003c/p\u003e\n\u003cp\u003eThe allocation of participants in this study will be performed through a process of computer-generated random numbers. The enrolled participants will be randomly assigned to one of two groups: the vitrectomy combined with intravitreal dexamethasone implant group, and the vitrectomy-only group. The ratio of participants assigned to each group will be 1:1, without any additional stratification.\u003c/p\u003e\n\u003cp\u003eTo ensure the integrity of the randomization process, the randomized numbers will be generated by a computer and provided in a separate document. This document will remain inaccessible to individuals involved in patient enrollment or the performance of vitrectomy. By maintaining the confidentiality of the randomized number assignment, we aim to minimize any potential biases or influences on participant allocation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConcealment mechanism {16b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned.\u003c/p\u003e\n\u003cp\u003eThe randomization design will use permuted block sizes of 4 and 6 with the participant assignments placed in opaque, sealed, and serially numbered envelopes and individualized for each participant.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eImplementation {16c}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions.\u003c/p\u003e\n\u003cp\u003eThe randomization schedule will be generated by the data analyst (ZM), who will deliver this document in a sealed envelope to the surgeon (LJP) responsible for assigning the participants to the two groups.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAssignment of interventions: Blinding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eWho will be blinded {17a}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how.\u003c/p\u003e\n\u003cp\u003eIn this randomized, blind controlled trial protocol, it is crucial to maintain blinding for both the participants and the data analyst after assignment to the intervention groups.\u003c/p\u003e\n\u003cp\u003eTo ensure participant blinding, measures will be taken to prevent participants from discerning their assigned treatment group. This may include the use of identical packaging or labeling for both interventions, as well as avoiding any explicit communication or disclosure regarding the treatment received.\u003c/p\u003e\n\u003cp\u003eSimilarly, the data analyst responsible for data analysis and outcome assessments will be kept blind to the treatment allocation. This can be achieved by withholding information regarding the assigned interventions in the data provided for analysis. Additionally, any identifying details that may inadvertently reveal the treatment group will be masked or removed from the dataset.\u003c/p\u003e\n\u003cp\u003eHowever, it should be noted that the surgeon performing the vitrectomy and the ophthalmologists in charge of follow-up evaluations will not be blind to the interventions. Due to the nature of the study, the intravitreal dexamethasone implant used in one of the intervention groups can be visually identified in the vitreous during vitrectomy and in follow-up examinations. Therefore, blinding of the surgical team and the follow-up ophthalmologist is not feasible in this study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProcedure for unblinding if needed {17b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant\u0026rsquo;s allocated intervention during the trial.\u003c/p\u003e\n\u003cp\u003eUnblinding of participants to their assigned interventions will be conducted under specific circumstances, following predefined criteria. The unblinding procedure will be implemented as outlined below:\u003c/p\u003e\n\u003cp\u003eIf a participant\u0026apos;s overall health condition significantly worsens and poses a threat to their life, unblinding will be initiated to ensure appropriate medical management and intervention.\u003c/p\u003e\n\u003cp\u003eIn cases where the participant experiences elevated intraocular pressure (IOP) exceeding 30 mmHg, with suboptimal response to medication, unblinding will be considered.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eUnblinding may also occur if the participant develops intraocular inflammation, indicating the need for specialized treatment and care.\u003c/p\u003e\n\u003cp\u003eThe process of unblinding will be carefully conducted by authorized individuals who are not involved in the primary assessment or outcome evaluation. These individuals will have access to the allocation information, which will remain confidential throughout the study duration. If or emergency unblinding occurs in more than 20% of cases before the completion of the trial, it will be deemed a failure of the double-blind trial.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData collection and management\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePlans for assessment and collection of outcomes {18a}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol.\u003c/p\u003e\n\u003cp\u003eTo ensure data quality, we employ various processes, including duplicate measurements and rigorous training of assessors.\u003c/p\u003e\n\u003cp\u003eThe data will be entered through a on-line web browser input form designed at JanDao Cloud platform. The Epidata EDC system will be used for data collection. Patient data will be documented by dedicated trial personnel and managed in the eCRF. All staff involved in the data collection process are to be qualified to access the research database.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eOur study utilizes specialized ophthalmic examination and surgical equipment, including standard devices for intraocular pressure measurement, visual acuity assessment, vitrectomy and OCT scans. All measurements strictly adhere to clinical trial protocols, ensuring data precision and accuracy for proliferative diabetic retinopathy vitrectomy procedures.\u003c/p\u003e\n\u003cp\u003eThe data entry forms are stored within the JianDao Cloud platform, where duly authorized researchers gain access through mobile phone number verification.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePlans to promote participant retention and complete follow-up {18b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols.\u003c/p\u003e\n\u003cp\u003eTo ensure participant retention and data completeness, we will emphasize the importance of scheduled follow-up appointments through education. During clinical encounters, we\u0026apos;ll discuss and schedule follow-up visits with participants and their families. Additionally, a designated staff member will perform telephone follow-ups for participants exceeding a two-week follow-up gap. To address potential non-compliance or attrition, we\u0026apos;ve outlined specific outcome data collection. This streamlined approach aims to maximize research integrity and data collection even in cases of participant non-compliance or attrition.\u003c/p\u003e\n\u003cp\u003eOne of the following outcome data will be collected for participants who discontinue the study: 1) Patients completing a 6-month follow-up; 2) Patients undergoing secondary surgery due to retinal detachment with non-repositioning or non-absorption of vitreous hemorrhage; 3) Patients undergoing glaucoma surgery due to inadequate control with ocular hypotensive medications (including secondary to fillers, uncontrolled neovascular glaucoma, medication-induced); 4) Incidence of intraocular inflammation; 5) Surgical removal of implant dislocated into the anterior chamber; 6) Deterioration of general health preventing follow-up; 7) Visual loss or patient discontinuation of treatment during follow-up.\u003c/p\u003e\n\u003cp\u003eMonthly reviews of clinical research issues are conducted, categorized by deviation severity. All protocol deviations are documented in a Protocol Deviation Report, detailing discovery time, event timelines, reasons, and corrective actions. Severe deviations affecting subject rights, safety, or data integrity are reported to regulatory authorities and ethics committees, outlined in the research plan. In blinded studies, protocol deviations are managed separately for blinded and unblinded teams, with specialized unblinded team review. Severe deviations may lead to data exclusion from specific analysis populations. Mild deviations, not classified as severe, won\u0026apos;t trigger data exclusion unless they recur and become severe.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData management {19}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol.\u003c/p\u003e\n\u003cp\u003eData collection entails a meticulous process characterized by the independent entry of data by two trained staff members. Subsequently, Epidata is utilized to assess data consistency. In cases of inconsistency, a third staff is involved for data verification and validation. This rigorous protocol ensures data integrity, aligning with the highest standards of research precision.\u003c/p\u003e\n\u003cp\u003eThe principal investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConfidentiality {27}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial.\u003c/p\u003e\n\u003cp\u003eWe prioritize participant data confidentiality throughout the trial, in compliance with national data protection laws and WHO Good Clinical Practice guidelines. All patient data, including case report forms, is securely managed to maintain privacy during and after the trial.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePlans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable.\u003c/p\u003e\n\u003cp\u003eN/a\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical methods\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical methods for primary and secondary outcomes {20a}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol.\u003c/p\u003e\n\u003cp\u003eThis study used R for statistical analysis of data.\u0026nbsp;A P-value\u0026thinsp;\u0026lt;\u0026thinsp;0,05 will be considered as statistically significant.\u003c/p\u003e\n\u003cp\u003eVisual acuity and OCT measurements were analyzed using repeated measures analysis of variance with two-tailed tests;\u003c/p\u003e\n\u003cp\u003eRates of visual improvement, visual decline,\u0026nbsp;the\u0026nbsp;occurrence of postoperative vitreous hemorrhage, elevated intraocular pressure and postoperative retinal detachment were analyzed using chi-square tests with two-tailed tests;\u003c/p\u003e\n\u003cp\u003eDescriptive statistics: Normal continuous data were described using mean and standard deviation; non-normally distributed continuous data were described using median and quartiles; categorical variables were described using proportions and rates;\u003c/p\u003e\n\u003cp\u003eGrouping variables: For continuous data, t-tests or rank-sum tests were used; for categorical variables, chi-square tests or Fisher\u0026apos;s exact tests were used;\u003c/p\u003e\n\u003cp\u003eAnalysis of risk factors for poor visual prognosis, neovascular glaucoma development, and postoperative vitreous hemorrhage occurrence was conducted using logistic regression analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInterim analyses {21b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial.\u003c/p\u003e\n\u003cp\u003eInterim analysis will be conducted after 1 year of study initiation or when 50% of the medical records have been collected. The interim analysis will be carried out by PI and members who are in charge of statistic analysis, who will then decide whether to terminate the trial based on the results.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods for additional analyses (e.g. subgroup analyses) {20b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Methods for any additional analyses (eg, subgroup and adjusted analyses).\u003c/p\u003e\n\u003cp\u003eThere are no planned subgroup analyses.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Definition of analysis population relating to protocol non-adherence (eg, as randomized analysis), and any statistical methods to handle missing data (eg, multiple imputation).\u003c/p\u003e\n\u003cp\u003eDescriptive statistical analysis was conducted on the population of enrolled participants who completed the 12-week follow-up. Participants who did not adhere to the study protocol were subject to data exclusion, which was determined by the data statistician based on individual patient circumstances. Lost-to-follow-up data were analyzed by the data statistician based on individual patient circumstances using a direct exclusion method.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePlans to give access to the full protocol, participant level-data and statistical code {31c}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code.\u003c/p\u003e\n\u003cp\u003eAccess to the protocol and the results will be granted on reasonable request to the authors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOversight and monitoring\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eComposition of the coordinating centre and trial steering committee {5d}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTrials guidance: Provide information on the composition, roles and responsibilities of the coordinating centre and trial steering committee and all groups providing day to day support for the trial. \u0026nbsp;There will always be a group running the trial day-to-day and providing organisational support and knowing how often they will meet, plus information on other committees providing oversight such as a Trial Steering Committee, and how often they will meet over the course of the trial, is what we need for item 5d. \u0026nbsp; We do not need names of staff.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee).\u003c/p\u003e\n\u003cp\u003eThis is a single center research. This investigator-initiated trial will be coordinated by the Department of Ophthalmology in Beijing Tongren eye center. The evaluation of the study progress will be done monthly.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eComposition of the data monitoring committee, its role and reporting structure {21a}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed.\u003c/p\u003e\n\u003cp\u003eNo special data monitoring is needed for this single-center research.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdverse event reporting and harms {22}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct.\u003c/p\u003e\n\u003cp\u003eAny adverse medical events occurring from the patient\u0026apos;s signing of the informed consent form to their last follow-up, whether causally related to the experimental drug, are considered adverse events. These events are reported and managed following hospital protocols, and records include event timing, severity, duration, interventions, and outcomes.\u003c/p\u003e\n\u003cp\u003eAdverse events are defined as those resulting in death, life-threatening situations, hospitalization, extended hospital stays, or permanent/severe disability/loss of function. After an adverse event, it is reported to relevant departments, and management follows the guidance of department consultations, adhering to hospital protocols.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFrequency and plans for auditing trial conduct {23}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor.\u003c/p\u003e\n\u003cp\u003eThe trial will be audited by the ethics committee of Beijing Tongren hospital on a yearly basis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePlans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators).\u003c/p\u003e\n\u003cp\u003eWe will communicate the important protocol modifications with ethics committee for approval. The approved changes of the protocol will be discussed with investigators and trail registries.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDissemination plans {31a}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions.\u003c/p\u003e\n\u003cp\u003eWe plan to communicate trail results to participants, healthcare professionals and public via publication, reporting in results databases.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003e \u003cem\u003eTrials\u003c/em\u003e guidance: This should include a discussion of any practical or operational issues involved in performing the study and any issues not covered in other sections.\u003c/p\u003e \u003cp\u003eThis study is a prospective randomized controlled trial, and there is no similar research available on the efficacy of intravitreal dexamethasone combined with vitrectomy in the treatment of PDR. Prior studies have confirmed that the incidence of macular edema following pars plana vitrectomy in PDR patients is high, making it one of the primary factors affecting visual prognosis [4]. Therefore, this study aims to shed light on the role of intravitreal dexamethasone in alleviating macular edema and improving visual outcomes in PDR patients after vitrectomy.\u003c/p\u003e \u003cp\u003eA key issue in this research lies in the execution of blinding. The dexamethasone drug used in the study is white in colour. To minimize any potential influence on the surgeon's decisions during vitrectomy, we chose to unmask and administer the injection at the time of closing the incisions. During follow-up, the implant may be located either in the vitreous cavity or anterior to the retina and may be visible. Therefore, the informed consent documents for patients explicitly state that patients should not be concerned about the presence or absence of linear shadows post-surgery and should adhere to the scheduled follow-up visits. However, for the physicians responsible for postoperative examinations, indirect ophthalmoscopy fundus examination may reveal the presence of the implant in the vitreous cavity. Therefore, blinding is not feasible for postoperative follow-up doctors, surgeons at the end of the surgery, and patients who perceive distinctive dark shadows in their vision. However, blinding can be maintained for the surgeon preoperatively, patients preoperatively, individuals involved in data collection and analysis, and patients without clear distinctive dark shadows postoperatively. As a result, this study is a clinical research utilizing blinding in a single-blind, randomized controlled trial manner and cannot achieve double-blinding.\u003c/p\u003e \u003cp\u003eDue to the majority of patients being non-local, postoperative follow-up poses some challenges. We have employed strategies such as preoperative education on the importance of post-vitrectomy follow-up, pre-scheduled appointments, and the use of follow-up forms to remind both the follow-up doctors and patients to ensure timely completion of follow-up visits. During the follow-up process, a designated person is responsible for promptly identifying patients who have not attended follow-up visits for more than two weeks. We will communicate with these patients through phone calls to encourage them to return for follow-up, and for those unable to visit, PI is responsible for conducting telephone tracking as outlined in the pre-designed tracking protocol and rearranging the missed follow-up for the patients.\u003c/p\u003e \u003cp\u003eIn the statistical analysis, vision and OCT thickness measurements are subjected to repeated-measures analysis of variance. To ensure that the results are minimally affected by measurement variations across different devices, we employ the same measurement personnel for corrected vision measurement and the same instrument for OCT retinal thickness measurement. To ensure an adequate sample size for the efficacy analysis of diabetic retinopathy macular edema, we estimated the sample size based on reported rates from prior literature and our pre-experimental results of postoperative macular edema incidence, adding a 10\u0026ndash;15% of dropout rate of the participants during the 24-week follow-up.\u003c/p\u003e\n\u003ch3\u003eTrial status\u003c/h3\u003e\n\u003cp\u003e \u003cem\u003eTrials\u003c/em\u003e guidance: Authors should report the protocol version number and date, the date recruitment began, and the approximate date when recruitment will be completed.\u003c/p\u003e \u003cp\u003eThe version of the protocol is 20220909. The date of the approval of the protocol is September 29th, 2022. The recruitment began at November 23th, 2022, it will be completed at December 4th, 2023.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003e\u003cem\u003eTrials\u003c/em\u003e guidance: If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations should be provided.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\"\u003e\n \u003cp\u003eCRT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"72.69439421338156%\" valign=\"top\"\u003e\n \u003cp\u003ecentral retinal thickness\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\"\u003e\n \u003cp\u003eDME\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"72.69439421338156%\" valign=\"top\"\u003e\n \u003cp\u003ediabetic macular edema\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\"\u003e\n \u003cp\u003eDR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"72.69439421338156%\" valign=\"top\"\u003e\n \u003cp\u003ediabetic retinopathy\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\"\u003e\n \u003cp\u003eFVM\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"72.69439421338156%\" valign=\"top\"\u003e\n \u003cp\u003efibrovascular vascular membranes\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\"\u003e\n \u003cp\u003eIVR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"72.69439421338156%\" valign=\"top\"\u003e\n \u003cp\u003eintravitreal ranibizumab\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\"\u003e\n \u003cp\u003ePDR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"72.69439421338156%\" valign=\"top\"\u003e\n \u003cp\u003eproliferative diabetic retinopathy\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\"\u003e\n \u003cp\u003ePI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"72.69439421338156%\" valign=\"top\"\u003e\n \u003cp\u003eprimary investigator\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\"\u003e\n \u003cp\u003eOCT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"72.69439421338156%\" valign=\"top\"\u003e\n \u003cp\u003eoptic\u0026nbsp;coherence tomography\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\"\u003e\n \u003cp\u003eVH\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"72.69439421338156%\" valign=\"top\"\u003e\n \u003cp\u003evitreous hemorrhage\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTrials\u003c/em\u003e guidance: Please acknowledge anyone who contributed towards the article who does not meet the criteria for authorship including anyone who provided professional writing services or materials. Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section. See our editorial policies for a full explanation of acknowledgements and authorship criteria. If you do not have anyone to acknowledge, please write \u0026quot;Not applicable\u0026quot; in this section.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe thank the technicians who check the corrected visual acuity and OCT CRT measurement, the fellow resident who will oversee the patients when they undergo vitrectomy, the nurses who will oversee the education of PDR during the patients stay in the hospital. All their work will contribute to the accuracy of the data and good compliance of the PDR patients.\u003c/p\u003e\n\u003cp\u003eGroup authorship (for manuscripts involving a collaboration group): if you would like the names of the individual members of a collaboration Group to be searchable through their individual PubMed records, please ensure that the title of the collaboration Group is included on the title page and in the submission system and also include collaborating author names as the last paragraph of the \u0026ldquo;Acknowledgements\u0026rdquo; section. Please add authors in the format First Name, Middle initial(s) (optional), Last Name. You can add institution or country information for each author if you wish, but this should be consistent across all authors. Please note that individual names may not be present in the PubMed record at the time a published article is initially included in PubMed as it takes PubMed additional time to code this information.\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions {31b}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: [31b] - Authorship eligibility guidelines and any intended use of professional writers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTrials\u003c/em\u003e guidance: The individual contributions of authors to the manuscript should be specified in this section. Guidance and criteria for authorship can be found in our editorial policies. Please use initials to refer to each author\u0026apos;s contribution in this section, for example: \u0026quot;AB is the Chief Investigator; she conceived the study, led the proposal and protocol development. CD contributed to study design and to development of the proposal. EF was the lead trial methodologist. All authors read and approved the final manuscript.\u0026quot;\u003c/p\u003e\n\u003cp\u003eJipeng Li is the primary investigator, he led the proposal and protocol development.\u003c/p\u003e\n\u003cp\u003eMeng Zhao contributed to study design and to development of the proposal, she was the trail methodologist.\u003c/p\u003e\n\u003cp\u003eJun Xu is in charge of disclose the blind and the follow-up of the patients.\u003c/p\u003e\n\u003cp\u003eLin Liu is in charge of scheduling the visiting of the patients, entering data and store the record sheet and education about the follow-up.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAman Chandra\u0026nbsp;is in charge of study design, supervision of the study data collection, revising the manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding {4}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Sources and types of financial, material, and other support.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTrials\u003c/em\u003e guidance: All sources of funding for the research reported should be declared. You will be required to include a copy of the original funding document and an English translation of this document as an additional file on submission, which will be checked against this declaration. The role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript should be declared.\u003c/p\u003e\n\u003cp\u003eNo funding.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials {29}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTrials\u003c/em\u003e guidance: Please do not include any baseline or pilot data in your study protocol. The Editorial Office will ask you to remove this if it is included. Please declare here who will have access to the final trial dataset and disclose contractual agreements that limit such access for investigators.\u003cbr\u003e\u0026nbsp;In this study, only members of the research team will have access to the data.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate {24}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Plans for seeking research ethics committee/institutional review board (REC/IRB) approval.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTrials\u003c/em\u003e guidance: Trials do not consider study protocols for studies without ethical approval. You will be required to provide a copy of the original ethical approval document and an English translation of this document as an additional file on submission, which will be checked against this declaration. The name of the ethics committee that approved the study and the committee\u0026rsquo;s reference number (if applicable) should be declared. Details of authors\u0026rsquo; intentions to obtain consent to participate in the study from participants (or their parent or legal guardian in the case of children under 16) should be declared. \u0026ldquo;eg. ABC Ethical Review Board ABC123456. Written, informed consent to participate will be obtained from all participants\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eThe study followed the tenets of the Declaration of Helsinki and the protocol and was approved by the Institutional Review Board of Beijing Tongren Hospital (TREC2022-KY063) at 30th August 2022. Patients were required to sign an informed consent form, and written informed consent was obtained from each participant.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication {32}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Model consent form and other related documentation given to participants and authorised surrogates.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTrials\u003c/em\u003e guidance: Please do not include any baseline or pilot data in your study protocol. The Editorial Office will ask you to remove this if it is included. If you have included any details, images or videos relating to an individual person, written informed consent for the publication of these details must be obtained from that person (or their parent or legal guardian in the case of children under 18) and declared in this section. Please also state whether you will be willing to provide a model consent form on request. If this section does not apply, please state \u0026ldquo;Not applicable\u0026rdquo;.\u003cbr\u003e\u0026nbsp; \u0026nbsp;Not applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests {28}\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPIRIT guidance: Financial and other competing interests for principal investigators for the overall trial and each study site.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTrials\u003c/em\u003e guidance: All financial and non-financial competing interests must be declared in this section. See our editorial policies for a full explanation of competing interests. If you are unsure whether you or any of your co-authors have a competing interest please contact the editorial office. Please use the authors initials to refer to each authors\u0026apos; competing interests in this section. If you do not have any competing interests, please state: \u0026quot;The authors declare that they have no competing interests\u0026quot; in this section.\u003cbr\u003e\u0026nbsp;The authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u003c/strong\u003e\u003cstrong\u003e\u0026rsquo;\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003einformation (optional)\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTrials\u003c/em\u003e guidance: This section is optional.\u003c/p\u003e\n\u003cp\u003eYou may choose to use this section to include any relevant information about the author(s) that may aid the reader\u0026apos;s interpretation of the article, and understand the standpoint of the author(s). This may include details about the authors\u0026apos; qualifications, current positions they hold at institutions or societies, or any other relevant background information. Please refer to authors using their initials. Note this section should not be used to describe any competing interests.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eFlaxman, Bourne, Resnikoff\u003cem\u003e et al.\u003c/em\u003e Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. \u003cem\u003eLancet Glob Health\u003c/em\u003e 2017;5: e1221-e1234, doi:10.1016/s2214-109x(17)30393-5.\u003c/li\u003e\n\u003cli\u003eLiu, Wu, Liu\u003cem\u003e et al.\u003c/em\u003e Prevalence of diabetic retinopathy in mainland China: a meta-analysis. \u003cem\u003ePloS one\u003c/em\u003e 2012;7: e45264-e45264, doi:10.1371/journal.pone.0045264.\u003c/li\u003e\n\u003cli\u003eStewart, Browning \u0026amp; Landers. Current management of diabetic tractional retinal detachments. \u003cem\u003eIndian J Ophthalmol\u003c/em\u003e 2018;66: 1751-1762, doi:10.4103/ijo.IJO_1217_18.\u003c/li\u003e\n\u003cli\u003eSchreur, Brouwers, Van Huet\u003cem\u003e et al.\u003c/em\u003e Long-term outcomes of vitrectomy for proliferative diabetic retinopathy. \u003cem\u003eActa Ophthalmol\u003c/em\u003e 2021;99: 83-89, doi:10.1111/aos.14482.\u003c/li\u003e\n\u003cli\u003eYau, Silva, Arrigg\u003cem\u003e et al.\u003c/em\u003e Postoperative Complications of Pars Plana Vitrectomy for Diabetic Retinal Disease. \u003cem\u003eSeminars in ophthalmology\u003c/em\u003e 2018;33: 126-133, doi:10.1080/08820538.2017.1353832.\u003c/li\u003e\n\u003cli\u003eRittiphairoj, Mir, Li\u003cem\u003e et al.\u003c/em\u003e Intravitreal steroids for macular edema in diabetes. \u003cem\u003eCochrane Database Syst Rev\u003c/em\u003e 2020;11: Cd005656, doi:10.1002/14651858.CD005656.pub3.\u003c/li\u003e\n\u003cli\u003ePuliafito, Cousins, Bacharach\u003cem\u003e et al.\u003c/em\u003e Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema. \u003cem\u003eOphthalmic Surg Lasers Imaging Retina\u003c/em\u003e 2016;47: S4-s15, doi:10.3928/23258160-20160224-01.\u003c/li\u003e\n\u003cli\u003eEhlers, Yeh, Maguire\u003cem\u003e et al.\u003c/em\u003e Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. \u003cem\u003eOphthalmology\u003c/em\u003e 2022;129: 88-99, doi:10.1016/j.ophtha.2021.07.009.\u003c/li\u003e\n\u003cli\u003eBoyer, Faber, Gupta\u003cem\u003e et al.\u003c/em\u003e Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. \u003cem\u003eRetina\u003c/em\u003e 2011;31: 915-923, doi:10.1097/IAE.0b013e318206d18c.\u003c/li\u003e\n\u003cli\u003eAltun, Kanar, Aki\u003cem\u003e et al.\u003c/em\u003e Effectiveness and Safety of Coadministration of Intravitreal Dexamethasone Implant and Silicone Oil Endotamponade for Proliferative Diabetic Retinopathy with Tractional Diabetic Macular Edema. \u003cem\u003eJ Ocul Pharmacol Ther\u003c/em\u003e 2021;37: 131-137, doi:10.1089/jop.2020.0079.\u003c/li\u003e\n\u003cli\u003eSomeya, Takayama, Takeuchi\u003cem\u003e et al.\u003c/em\u003e Outcomes of 25-Gauge Vitrectomy for Tractional and Nontractional Diabetic Macular Edema with Proliferative Diabetic Retinopathy. \u003cem\u003eJ Ophthalmol\u003c/em\u003e 2019;2019: 5304524, doi:10.1155/2019/5304524.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":true,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"trials","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"trls","sideBox":"Learn more about [Trials](http://trialsjournal.biomedcentral.com/)","snPcode":"13063","submissionUrl":"https://www.editorialmanager.com/trls","title":"Trials","twitterHandle":"MedicalEvidence","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"intravitreal dexamethasone implant, vitrectomy, proliferative diabetic retinopathy","lastPublishedDoi":"10.21203/rs.3.rs-3622174/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3622174/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: Proliferative diabetic retinopathy (PDR) often leads to tractional retinal detachment and vitreous hemorrhage, requiring vitrectomy. Poor visual outcomes are commonly caused by macular edema and proliferative vitreous retinopathy after vitrectomy. Intravitreal dexamethasone implant has shown promise in improving visual function after vitrectomy for diabetic macular edema, but its role in vitrectomy in PDR treatment remains unexplored. This study aims to assess the effectiveness of vitrectomy combined with intravitreal dexamethasone implant for PDR patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: We designed a single-blind, randomized controlled trial with 100 participants diagnosed with PDR requiring vitrectomy. Participants were randomly assigned to either the dexamethasone implant group or the control group. The dexamethasone implant group underwent vitrectomy combined with intravitreal dexamethasone implant, while the control group underwent vitrectomy alone. The single surgeon performed all the vitrectomy surgeries, the choice of intravitreal dexamethasone implant treatment was disclosed before the closure of scleral wounds. Primary and secondary outcomes were assessed at baseline, 4 weeks, and 8 weeks post-vitrectomy. Primary outcome measures included corrected visual acuity (Snellen visual chart) and central retinal thickness (optical coherence tomography OCT). Secondary outcomes included elevated intraocular pressure, post-vitrectomy hemorrhage, retinal detachment, and systemic complications requiring hospitalization.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDiscussion\u003c/strong\u003e: This protocol seeks to enhance our understanding of the effects of combined intravitreal dexamethasone implant with vitrectomy on visual outcomes and macular morphology changes in treating late complications of PDR.\u003c/p\u003e\n\u003cp\u003eThe trail was registered at Chinese Clinical Trial Registry at May 11\u003csup\u003eth\u003c/sup\u003e 2022 with registration number ChiCTR2200059760.\u003c/p\u003e","manuscriptTitle":"The effectiveness of vitrectomy co-adjuvant intravitreal dexamethasone implant on visual outcome in patients with proliferative diabetic retinopathy: study protocol for a prospective randomized controlled trail","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-04-03 17:01:46","doi":"10.21203/rs.3.rs-3622174/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"reviewerAgreed","content":"","date":"2024-04-10T16:38:11+00:00","index":0,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-03-29T11:32:38+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-02-15T08:06:32+00:00","index":"","fulltext":""},{"type":"submitted","content":"Trials","date":"2023-12-15T02:28:20+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"trials","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"trls","sideBox":"Learn more about [Trials](http://trialsjournal.biomedcentral.com/)","snPcode":"13063","submissionUrl":"https://www.editorialmanager.com/trls","title":"Trials","twitterHandle":"MedicalEvidence","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"8ec1f3eb-d381-43b2-832d-083adedcb594","owner":[],"postedDate":"April 3rd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-02-17T16:05:51+00:00","versionOfRecord":{"articleIdentity":"rs-3622174","link":"https://doi.org/10.1186/s13063-025-08758-1","journal":{"identity":"trials","isVorOnly":false,"title":"Trials"},"publishedOn":"2025-02-12 15:57:26","publishedOnDateReadable":"February 12th, 2025"},"versionCreatedAt":"2024-04-03 17:01:46","video":"","vorDoi":"10.1186/s13063-025-08758-1","vorDoiUrl":"https://doi.org/10.1186/s13063-025-08758-1","workflowStages":[]},"version":"v1","identity":"rs-3622174","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3622174","identity":"rs-3622174","version":["v1"]},"buildId":"cBFmMYwuxLRRLfASyISRj","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}